DWS Group GmbH & Co KGaA reports robust financial performance with significant net inflows and strategic initiatives, despite challenges in active equity strategies and market volatility.

Quarter Results/ForecastDrägerwerk AG & Co. KGaA: Dräger with strong demand in the first quarter of 2025 30.04.2025 / 07:30 CET/CESTThe issuer is solely responsible for the content of this ...

Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

ESG/SustainabilityAsklepios Group: Publication of Asklepios CSRD Report 2024 30.04.2025 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Asklepios Group: ...

Recent developments in health highlight key agreements between countries, drug approvals, corporate revenue growth, and ...

The Hormone Replacement Therapy Market is estimated to grow at a CAGR of 6.48% during the forecast period from 2024 to 2030.

We are pleased to share the April 2025 issue of Wilson Sonsini's Sustainability and ESG Advisory Practice Update. Each issue combines news, key ...

The health sector is abuzz with significant news: from FDA approvals of novel drugs and mergers like Merck's acquisition of ...

This practical note was originally published by Practical Law Capital Markets. A practice note setting out top tips from German counsel ...

AVTR to an Equal-Weight rating, reflecting concerns over financial performance. Avantor’s Q1 2025 earnings report showed an ...

This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily ...